A comprehensive new study has identified 13 priority research areas. These aim to guide the future rollout of Lassa fever vaccines across West Africa. The research appears in the International Journal of Infectious Diseases. It brings together experts from various public health and research bodies.
The study focuses on evidence needed before vaccines become widely available. Lassa fever is a serious disease common in West Africa. It spreads through contact with infected rodents. About 897,700 cases may occur yearly, though many go undetected. Severe cases can be fatal, with fatality rates up to 20%. Pregnant women face higher risks, with mortality over 30% and foetal loss up to 75%.
This new research follows concerns about the potential spread of Lassa fever. Environmental changes could worsen the situation. Ghana, like other West African nations, is already endemic for the disease. The study acknowledges that previous research focused more on developing vaccines than on their practical use. This gap is crucial as a vaccine could be available after 2030.
The research used a method called CHNRI. This helped experts rank essential research questions. Over 600 studies and expert interviews identified 83 evidence gaps. These were narrowed to 29 research questions. They covered epidemiology, vaccine trials, economic studies, and public acceptance. A survey of 235 respondents confirmed strong agreement. Research questions with direct policy relevance ranked highest. This included economic impact studies.
Delays in understanding implementation needs could slow vaccine introduction. Researchers cited the long process for the RTS,S malaria vaccine. Early preparation is vital for safe and effective Lassa fever vaccine rollout. Governments played a large role in the survey. Government representatives formed over half the respondents. This highlights their importance in decision-making.
The West African Health Organization (WAHO) is expected to lead efforts. They will integrate these priorities into a regional plan. Preparing for Lassa fever vaccines involves more than just development. It requires generating evidence for policy and rollout strategies. The study calls for these priorities to become funded research projects and pilot programs. National governments, research bodies, and aid agencies should align their work with this agenda.